Neurotrope Bioscience’s lead Alzheimer’s drug candidate, bryostatin, promotes the formation of new synapses in the brains of mice, according to the study, “PKC epsilon Promotes Synaptogenesis through Membrane accumulation of the Postsynaptic Density Protein PSD-95,” recently published in the Journal of Biological Chemistry. Synaptogenesis and synaptic maturation are two…
NeuroVision Imaging has raised $10 million in new funding through a Series B financing round, led by a $5 million investment from Wildcat Capital Management. The funds will support NeuroVision’s research on retinal imaging technology, a potential new approach to amyloid detection in Alzheimer’s disease (AD). A particular…
Alzheimer’s disease has been described in medical literature for more than a century, but still has no effective treatments. Now, scientists at the Salk Institute in La Jolla, California, report finding evidence that tetrahydrocannabinol (THC), one of several physiologically active chemical compounds in marijuana, can promote cellular removal of amyloid beta, a toxic…
New York City-based Intra-Cellular Therapies has started its ITI-007-201 Phase 3 clinical trial for the treatment of agitation in patients with dementia, including Alzheimer’s disease, following the company’s communication with the U.S. FDA. Intra-Cellular Therapies Chairman and CEO Dr. Sharon Mates said in a press release she is pleased that…
In an effort to promote education about Alzheimer’s disease and help local communities plan for this emerging public health crisis, Eli Lilly and Company has started an expansion of its “Community Conversations on Alzheimer’s” series with a panel discussion at the U.S. Conference of Mayors June 24-27 in Indianapolis.
Using slices of mouse brain tissue kept alive in a lab dish, scientists have identified the earliest molecular changes leading to Alzheimer’s disease. The findings, showing how early alterations in brain amyloid-β balance causes nerve connections called synapses to die, might allow scientist to target the mechanisms and develop therapies to…
vTv Therapeutics is recruiting patients for a large Phase 3 study, known as STEADFAST, assessing the drug azeliragon as a potential treatment for mild Alzheimer’s disease (AD). Study participants will be randomly assigned to take either a 5 mg pill containing azeliragon once a day, or a placebo (sugar pill), for 18 months, with…
Unbalanced, unhealthy zinc levels show in many diseases including Alzheimer’s disease, Parkinson’s disease, and pancreatic cancer. But lack of information about the molecular structure of zinc transporters hampers the discovery of new drugs to bring zinc to proper levels (homeostasis) with other important elements. Researchers at Michigan State University (MSU) have taken a new step toward the development of…
Two studies from the Washington University School of Medicine in St. Louis, Missouri, reveal new insights into amyloid-β — the plaque-forming protein scientists believe is at the root of Alzheimer’s disease. Both studies homed in on the removal of amyloid-β from the brain, a process thought to be defective in Alzheimer’s…
Scientists at the Buck Institute for Research on Aging recently demonstrated that memory loss for patients with early Alzheimer’s disease can be reversed — a feat the research team managed through a 36-point approach called metabolic enhancement for neurodegeneration. The multidisciplinary program is the first to show that cognitive decline and…
Get regular updates to your inbox.